Ranolazine is a novel antianginal medication approved for the treatment of chronic angina. There are only limited data concerning the efficacy of ranolazine in reducing healthcare resource utilization in patients with refractory angina pectoris.
Pharmacology, Toxicology and Pharmaceutical Science
1
4%
Agricultural and Biological Sciences
1
4%
Computer Science
1
4%
Other
2
7%
Unknown
10
37%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 December 2013.
All research outputs
#18,355,685
of 22,733,113 outputs
Outputs from American Journal of Cardiovascular Drugs
#352
of 425 outputs
Outputs of similar age
#147,794
of 197,254 outputs
Outputs of similar age from American Journal of Cardiovascular Drugs
#5
of 7 outputs
Altmetric has tracked 22,733,113 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 425 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 8th percentile – i.e., 8% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,254 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.
